Yu W Huang

US Patent:

20220367001, Nov 17, 2022

Filed:

May 25, 2022

Appl. No.:

17/824098

Inventors:

- Tarrytown NY, US
Yu Huang - Ossining NY, US

International Classification:

G16B 5/20
G06F 17/11
G01N 33/68

Abstract:

Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.

US Patent:

20230089727, Mar 23, 2023

Filed:

Sep 16, 2022

Appl. No.:

17/946757

Inventors:

- Tarrytown NY, US
Yu Huang - Ossining NY, US
Xiaojing Zheng - Gaithersburg MD, US
Ning Li - New Canaan CT, US

International Classification:

G01N 33/68
G01N 30/72
G01N 30/88
G01N 30/86

Abstract:

The present invention generally pertains to methods of characterizing at least one protein of interest in a biological sample. In particular, the present invention pertains to the use of automated iterative tandem mass spectrometry (AIMS) to identify, quantify and characterize at least one protein of interest and/or biomarker from a biological sample such as plasma.

US Patent:

20190237157, Aug 1, 2019

Filed:

Jan 31, 2019

Appl. No.:

16/264044

Inventors:

- Tarrytown NY, US
Yu Huang - Ossining NY, US

International Classification:

G16B 5/20
G06F 17/11

Abstract:

Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.